231 related articles for article (PubMed ID: 25968154)
1. Letter: tumour necrosis factor alpha blocker switching--a not so simple pharmacokinetic. Authors' reply.
Gisbert JP; Chaparro M
Aliment Pharmacol Ther; 2015 Jun; 41(12):1302-3. PubMed ID: 25968154
[No Abstract] [Full Text] [Related]
2. Letter: tumour necrosis factor alpha blocker switching--a not so simple pharmacokinetic.
Licinio R; Losurdo G; Ierardi E; Di Leo A; Principi M
Aliment Pharmacol Ther; 2015 Jun; 41(12):1302. PubMed ID: 25968153
[No Abstract] [Full Text] [Related]
3. Letter: switching from one to another anti-tumour necrosis factor alpha agent, and the risks of an overlap of exposure--authors' reply.
Gisbert JP; Chaparro M
Aliment Pharmacol Ther; 2016 May; 43(9):1020. PubMed ID: 27040169
[No Abstract] [Full Text] [Related]
4. Letter: switching from one to another anti-tumour necrosis factor alpha agent, and the risks of an overlap of exposure.
Macaluso FS; Criscuoli V; Orlando E; Rizzuto G; Renna S; Cottone M; Orlando A
Aliment Pharmacol Ther; 2016 May; 43(9):1019-20. PubMed ID: 27040168
[No Abstract] [Full Text] [Related]
5. The future of inflammatory bowel disease care.
Sandborn WJ
Rev Gastroenterol Disord; 2009; 9(3):E69-77. PubMed ID: 19898267
[TBL] [Abstract][Full Text] [Related]
6. Molecular mechanisms of action of anti-TNF-α agents - Comparison among therapeutic TNF-α antagonists.
Mitoma H; Horiuchi T; Tsukamoto H; Ueda N
Cytokine; 2018 Jan; 101():56-63. PubMed ID: 27567553
[TBL] [Abstract][Full Text] [Related]
7. Systematic review with meta-analysis: the efficacy of a second anti-TNF in patients with inflammatory bowel disease whose previous anti-TNF treatment has failed.
Gisbert JP; Marín AC; McNicholl AG; Chaparro M
Aliment Pharmacol Ther; 2015 Apr; 41(7):613-23. PubMed ID: 25652884
[TBL] [Abstract][Full Text] [Related]
8. Increased hospitalizations in elderly with inflammatory bowel disease on anti-tumor necrosis factor therapy but not increased infections: a community practice experience.
Shen H; Lipka S; Katz S
J Crohns Colitis; 2014 Aug; 8(8):898-9. PubMed ID: 24434182
[No Abstract] [Full Text] [Related]
9. IBD: Can TNF inhibitors be administered during the third trimester?
Nielsen OH; Jess T
Nat Rev Gastroenterol Hepatol; 2013 Mar; 10(3):130-1. PubMed ID: 23247511
[No Abstract] [Full Text] [Related]
10. The use of biologic agents in pregnancy and breastfeeding.
Horst S; Kane S
Gastroenterol Clin North Am; 2014 Sep; 43(3):495-508. PubMed ID: 25110255
[TBL] [Abstract][Full Text] [Related]
11. TNF inhibitors for Crohn's disease: when, which, and for how long.
Med Lett Drugs Ther; 2013 Dec; 55(1432):102-3. PubMed ID: 24419244
[No Abstract] [Full Text] [Related]
12. Certolizumab pegol (Cimzia) and ustekinumab (Stelara) for psoriatic arthritis.
Med Lett Drugs Ther; 2014 Feb; 56(1435):10-2. PubMed ID: 24662976
[No Abstract] [Full Text] [Related]
13. Anti-tumor necrosis factor agents and placental transfer: relevant clinical data for rational decision-making.
Kane S
Clin Gastroenterol Hepatol; 2013 Mar; 11(3):293-4. PubMed ID: 23247325
[No Abstract] [Full Text] [Related]
14. The classics in perspective.
Panés J; Ghosh S
Gut; 2007 Sep; 56(9):1184-6. PubMed ID: 17698863
[No Abstract] [Full Text] [Related]
15. T-cell non-Hodgkin's lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-α) inhibitors: results of the REFURBISH study.
Deepak P; Sifuentes H; Sherid M; Stobaugh D; Sadozai Y; Ehrenpreis ED
Am J Gastroenterol; 2013 Jan; 108(1):99-105. PubMed ID: 23032984
[TBL] [Abstract][Full Text] [Related]
16. Role of the tumor necrosis factor antagonists in the treatment of inflammatory bowel disease: an update.
Leso V; Leggio L; Armuzzi A; Gasbarrini G; Gasbarrini A; Addolorato G
Eur J Gastroenterol Hepatol; 2010 Jul; 22(7):779-86. PubMed ID: 19786877
[TBL] [Abstract][Full Text] [Related]
17. [TNF-alpha blocking therapy in chronic inflammatory bowel disease].
Molnár T
Orv Hetil; 2009 Sep; 150(38):1773-9. PubMed ID: 19740722
[TBL] [Abstract][Full Text] [Related]
18. Anti-TNF-alpha treatment strategies: results and clinical perspectives.
D'Haens G
Gastroenterol Clin Biol; 2009 Jun; 33 Suppl 3():S209-16. PubMed ID: 20117344
[TBL] [Abstract][Full Text] [Related]
19. [Current status of new drug development for inflammatory bowel diseases].
Kohgo Y; Tanabe H; Fujiya M
Nihon Rinsho; 2012 Feb; 70 Suppl 1():378-82. PubMed ID: 23126121
[No Abstract] [Full Text] [Related]
20. Novel biologics in inflammatory bowel disease.
Papachristou GI; Plevy S
Gastroenterol Clin North Am; 2004 Jun; 33(2):251-69, ix. PubMed ID: 15177537
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]